Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We present the case of a 40-year old female who was initially seen by her GP and the Emergency Department with pneumonia failing to respond to oral antibiotics. Her severity assessment score categorised her as being in a low risk group and she was discharged. Subsequent admission and further investigations diagnosed Human Immunodeficiency Virus infection and Pneumocystis jeruvici pneumonia. It is important for emergency departments and acute physicians to apply risk validation tools appropriately and to be alert to underlying immunosuppression.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Trauma video review: how long do we curb our enthusiasm?
Trauma Surg Acute Care Open
February 2025
Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Dexmedetomidine in paediatric anaesthesia: a call for action?
Br J Anaesth
August 2024
Department of Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine, University Hospitals of Geneva, Geneva, Switzerland; Geneva Neuroscience Center, University of Geneva, Geneva, Switzerland. Electronic address:
Dexmedetomidine is increasingly used in paediatric anaesthesia practice. In this issue of the British Journal of Anaesthesia, a retrospective hospital registry study in anaesthetised children showed that intraoperative use of dexmedetomidine was dose-dependently associated with a longer postanaesthesia care unit length of stay. Dexmedetomidine administration was also associated with higher total hospital costs and higher odds of unwarranted haemodynamic effects, while the onset of emergence delirium was not reduced.
View Article and Find Full Text PDFEarly Antibiotics in Septic Shock: A Desirable Goal but "Curb Your Enthusiasm".
Indian J Crit Care Med
July 2023
Department of Critical Care and Medicine, P.D. Hinduja Hospital, Mumbai, Maharashtra, India.
: Hegde A. Early Antibiotics in Septic Shock: A Desirable Goal but "Curb Your Enthusiasm". Indian J Crit Care Med 2023;27(7):459-460.
View Article and Find Full Text PDFGlycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective.
Front Pharmacol
February 2023
Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chimeric antigen receptor T (CAR T)-cell therapy promises to revolutionize the management of hematologic malignancies and possibly other tumors. However, the main side effect of cytokine release syndrome (CRS) is a great challenge for its clinical application. Currently, treatment of CRS caused by CAR T-cell therapy is limited to tocilizumab (TCZ) and corticosteroids in clinical guidelines.
View Article and Find Full Text PDF